Page 234 - 2021_06-Haematologica-web

1736
Letters to the Editor
3. Morgan GJ, Davies FE, Hawkins K, et al. Follow up analysis for MRC Myeloma VII Trial. Blood. 2004;104(11):927.
4. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose mel- phalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104(10):3052-3057.
5. Palumbo A, Cavallo F, Gay F, et al. Autologous transplantation and maintenance therapy in multiple myeloma. N Engl J Med. 2014;371(10):895-905.
6. Palumbo A, Gay F, Falco P, et al. Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolida- tion-maintenance in untreated multiple myeloma patients. J Clin Oncol. 2010;28(5):800-807.
7. Attal M, Lauwers-Cances V, Marit G, et al. Lenalidomide mainte- nance after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1782-1791.
8. Jackson GH, Davies FE, Pawlyn C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20(1):57-73.
9. McCarthy PL, Owzar K, Hofmeister CC, et al. Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med. 2012;366(19):1770-1781.
10. Cherniawsky H, Sandhu I, Chu MP, et al. The survival impact of lenalidomide maintenance chemotherapy in multiple myeloma patients treated with autologous stem cell transplant and borte- zomib-based induction: an analysis of real world data. Blood. 2017; 130(Suppl 1):S3132.
11. Cote J, Phillips M, Atenafu EG, et al. Pattern of first relapse in multi- ple myeloma (MM) patients (Pts) after a cybord induction regimen and autologous stem cell transplantation (ASCT): impact of mainte- nance therapy in the real-world setting. Blood. 2016;128(22):2137.
12. Yang C, Jiang H, Masih-Khan E, et al. Tolerability and efficacy of post transplant lenalidomide maintenance therapy in multiple myeloma: a real world single centre experience. Blood. 2017;130(Suppl 1):S3462.
13. Lonial S, Anderson KC. Association of response endpoints with sur- vival outcomes in multiple myeloma. Leukemia. 2014;28(2):258-268. 14. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group updated criteria for the diagnosis of mul-
tiple myeloma. Lancet Oncol. 2014;15(12):e538-e548.
15.Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;
17(8):e328-e346.
haematologica | 2021; 106(6)